In Q3 2023, Commodore Capital held 23 positions worth $629.4M. They initiated 6 new positions and exited 10. Their largest holding was VERA ($74.7M). Portfolio value shrank -2.5% versus the prior quarter.
Frequently asked questions
What stocks did Commodore Capital own in Q3 2023?
Commodore Capital held 23 biotech stocks in their 13F portfolio in Q3 2023. Their top positions include VERA, XENE, PCVX, COGT, RYTM. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Commodore Capital's portfolio worth in Q3 2023?
Commodore Capital's tracked biotech portfolio was worth $629.4M across 23 positions, with total assets under management of approximately $1.5B. Portfolio values are based on 13F filings with the SEC.
What did Commodore Capital buy in Q3 2023?
Commodore Capital initiated 6 new positions in Q3 2023, including RYTM, SLNO, CRNX, VTGN, APGE and 1 more. They also increased 6 existing positions.
What did Commodore Capital sell in Q3 2023?
Commodore Capital fully exited 10 positions in Q3 2023, including RZLT, RXDX, ENTA, RNA, ALLK and 5 more. They also trimmed 4 existing positions.
Is Commodore Capital a biotech fund?
Healthcare-focused investment firm co-founded by Egen Atkinson and Michael Kramarz. Takes concentrated positions in biotech and life sciences companies, combining deep scientific analysis with active portfolio management.
Want AI analysis, insider signals, and catalyst overlays for Commodore Capital?
View latest Commodore Capital portfolio →